TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04139655
Drug: Colchicine 0.6 mg
Normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral colchicine given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
Study: NCT00634751
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.
Study: NCT00634751
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).~Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length~Sorafenib 200 mg BID Oral Daily Every 28 days~If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.~Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length~Sorafenib 400 mg BID Oral Daily Every 28 days
Study: NCT03669614
Drug: Inhaled AR-501
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and multiple ascending doses of inhaled AR-501
Study: NCT00189436
Drug: Nebulized Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
Study: NCT00189436
Drug: Usual care (albuterol with or without oral steroid)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
Study: NCT04402385
Drug: Aspirin 81 mg
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to 81 mg of Aspirin daily
Study: NCT04469556
Drug: Gemcitabine/nab-paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT01287988
Drug: ocriplasmin
Normalized name: Ocriplasmin
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007
Study: NCT00442611
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03286634
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03286634
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03286634
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04274816
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of tremelimumab 7 days prior to sentinel node biopsy, with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
Study: NCT01406301
Drug: fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fondaparinux
Study: NCT03286634
Drug: 6-Mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03286634
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV, IT or SC
Study: NCT03865446
Drug: Dacomitinib
Normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-cancer agent
Study: NCT00069446
Drug: rhuMAb VEGF (telbermin)
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01511692
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.8 mg/day injected subcutaneously for 4 weeks
Study: NCT01511692
Drug: glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose individually adjusted, administered orally for 4 weeks
Study: NCT04349072
Drug: Mavacamten
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mavacamten Capsules Other names: MYK-461
Study: NCT02675907
Drug: N1539
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03401190
Drug: CM4620 Injectable Emulsion (Low Dose)
Normalized name: propofol lipid emulsion Injection
DrugBank: CM4620 (DB16466)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM4620-IE 1.0 mg/kg on Day 1 and then 1.4 mg/kg on Days 2-4, during the first phase of the study (Cohorts 1 and 2). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
Study: NCT00684463
Drug: Palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
Study: NCT00655122
Drug: Dalteparin sodium
Normalized name: Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
Study: NCT03401190
Drug: CM4620 Injectable Emulsion (High Dose)
Normalized name: propofol lipid emulsion Injection
DrugBank: CM4620 (DB16466)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM4620-IE 2.08 mg/kg on Days 1 and 2 and then 1.6 mg/kg on Days 3 and 4, during the second phase of the study (Cohorts 3 and 4). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
Study: NCT03712670
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: monthly intravitreal injections
Study: NCT03712670
Drug: Pranoprofen
Normalized name: pranoprofen
DrugBank: Pranoprofen (DB13514)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% pranoprofen 3 times a day topical eye drops administration
Study: NCT00405275
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: etanercept, subcutaneous injection
Study: NCT00405275
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulfasalazine, oral
Study: NCT00405275
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydroxychloroquine, oral
Study: NCT00971789
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects
Study: NCT03443453
Drug: MIV-711
Normalized name: MIV-711
DrugBank: MIV-711 (DB15599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIV-711 administered as tablets and capsules at four occasions
Study: NCT00405275
Drug: Placebo, etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants in triple arm (Arm 2) were given placebo etanercept injections.
Study: NCT00823225
Drug: Urokinase
Normalized name: Urokinase
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily infusion up to 21 applications, dose dependent on fibrinogen level:~\> 2,5g/l 1 000 000 IU, \< 2,5g/l 500 000 IU
Study: NCT04303156
Drug: Islatravir
Normalized name: Islatravir
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 60 mg Islatravir administered in capsule form
Study: NCT04356430
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg orally daily for 24 weeks before robotic assisted radical prostatectomy
Study: NCT04356430
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg oral low dose prednisone, once daily
Study: NCT04356430
Drug: Goserelin 10.8 mg
Normalized name: goserelin 10.8 MG
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10.8 mg goserelin hypodermic once per 12 weeks
Study: NCT00362869
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered at a dose of 500 mg once a day for 3 days
Study: NCT00608894
Drug: LCP-Tacro (tacrolimus)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
Study: NCT03180294
Drug: Bupropion 150 mg XL
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: By mouth
Study: NCT00467506
Drug: bispecific antibody and di-DTPA-131I
Normalized name: DTPA
DrugBank: Pentetic acid (DB14007)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02570711
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel infusion
Study: NCT02570711
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine infusion
Study: NCT00407771
Drug: Tirofiban
Normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01759420
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4mg of intravenous ondansetron
Study: NCT02242695
Drug: Canesten vaginal tablets
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one vaginal tablet for 7 days
Study: NCT00585533
Drug: Erlotinib (Tarceva)
Normalized name: erlotinib Oral Tablet [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib
Study: NCT03740009
Drug: Bazedoxifene/Conjugated Estrogen
DrugBank: Bazedoxifene (DB06401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg bazedoxifene/0.45mg conjugated estrogens tablets
Study: NCT00233337
Drug: Co-artemether
Normalized name: Lumefantrine co-artemether
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02202499
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
Study: NCT01129622
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
Study: NCT00004838
Drug: succimer
Normalized name: Succimer
DrugBank: Succimer (DB00566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04208061
Drug: Darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Darunavir orally.
Study: NCT01894776
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
Study: NCT01894776
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
Study: NCT01386229
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered
Study: NCT01386229
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
Study: NCT03622216
Drug: Bradanicline
Normalized name: Bradanicline
DrugBank: Bradanicline (DB06090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three different doses over the course of the study
Study: NCT02415595
Drug: BMS-955176
Normalized name: BMS-955176
DrugBank: BMS-955176 (DB15193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV Maturation Inhibitor
Study: NCT02415595
Drug: EFV
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EFV
Study: NCT00471315
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A preliminary, open-label single center study of duloxetine in patients with SOD
Study: NCT02614261
Drug: Galcanezumab
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT03304093
Drug: Nivolumab Injection
Normalized name: nivolumab Injection
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 3mg/kg every 2 weeks
Study: NCT00125892
Drug: duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00508469
Drug: Travoprost 0.004% eye drops
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
Study: NCT00508469
Drug: Timolol 0.05% eye drops
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
Study: NCT00224497
Drug: SB-742457
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04941976
Drug: 0.3% benzydamine hydrochloride spray oromucosal solution
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application of 0.3% benzydamine hydrochloride spray oromucosal solution. Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution.
Study: NCT04941976
Drug: Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)
Normalized name: benzydamine hydrochloride Oral Lozenge
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 3 mg lozenge of benzydamine hydrochloride (mint flavour). Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution.
Study: NCT00030004
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03189537
Drug: Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)
Normalized name: Ingavirin
DrugBank: Ingavirin (DB11944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antiviral agent
Study: NCT01480791
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
Study: NCT00886691
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00250029
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion \& the administration of any other drug.~Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 \& the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days.
Study: NCT03822780
Drug: Hydroxychloroquin
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg\*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg\*d to 10mg/kg\*d, p.o., bid ; the maximum daily dose is 400mg.
Study: NCT01365091
Drug: Saxagliptin/metformin fixed-dose combination (FDC)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
Study: NCT01365091
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral, 5 mg, once on Day 1 only, 1 day
Study: NCT01365091
Drug: Metformin extended-release (XR)
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, oral, 500 mg, once on Day 1 only, 1 day
Study: NCT01365091
Drug: Saxagliptin/Metformin FDC
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
Study: NCT01365091
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, oral, 1000 mg, once on Day 1 only, 1 day
Study: NCT00832689
Drug: Irinotecan and Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00583830
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle
Study: NCT00583830
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
Study: NCT03408886
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin is administered to reduce pathogenic bacteria.
Study: NCT03408886
Drug: MoviPrep
Normalized name: MoviPrep
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
Study: NCT01810770
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
Study: NCT01810393
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
Study: NCT03876704
Drug: High dose of fat-Soluble Vitamin
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation of 5 times current dose of fat-soluble vitamins by intravenous perfusion
Study: NCT03876704
Drug: Conventional dose of fat-Soluble Vitamin
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation of the current dose of fat-soluble vitamins by intravenous perfusion
Study: NCT01700140
Drug: SyB D-0701
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug patches \[Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch\] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
Study: NCT00419835
Drug: enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00419835
Drug: losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02817334
Drug: indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
Study: NCT01908296
Drug: fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT03059316
Drug: Nitroglycerin drug
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin is a drug used as an hypotensive agent through its vasodilation effect on veins